
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
Background In addition to progression-free survival (PFS) and overall survival (OS) benefits, first-line (1L) ribociclib plus endocrine therapy (ET) showed tolerable and manageable safety across the MONALEESA (ML) trials. Ribociclib plus ET is recommended …